Medical technology company AngioDynamics Inc (NASDAQ:ANGO) announced on Wednesday that it has initiated a global study to assess the long-term effects of its NanoKnife System in treating prostate cancer.
Conducted in partnership with University College London Hospital (UCLH), the study aims to validate the safety and efficacy of the NanoKnife System, which offers a less invasive alternative to traditional treatments.
By preserving vital structures inside and outside the prostate, the NanoKnife System seeks to minimise complications and improve patient quality of life.
TheraCryf signs Master Service Agreement with Pharmaron for Orexin-1 addiction programme
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
TransCode Therapeutics reports progress in metastatic cancer trial
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management